A Phase 2A Open-Label, Multicenter Trial of the Safety and Efficacy of LYC-55716, a First-in-class Oral, Small-Molecule RORγ Agonist to Treat Select Solid Tumors.

Karen Kelly,Melissa Lynne Johnson,Devalingam Mahalingam,Stephen V. Liu,Hope Elizabeth Uronis,Christina Wu,Laura Carter,Xiao Hu,Garry Alan Weems,H. Jeffrey Wilkins,Linda R. Duska

Journal of clinical oncology（2018）

引用 0|浏览31

暂无评分

摘要

TPS2617Background: LYC-55716 is a first-in-class, oral, small-molecule agonist of the retinoic acid receptor–related orphan receptor γ (RORγ) under development as a novel immuno-oncology agent for ...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要